Rafael Holdings Provides Update On Rafael Pharmaceuticals' Two Phase 3 Trials Of CPI-613, AVENGER 500 In Metastatic Pancreatic Cancer And ARMADA 2000 In Relapsed Or Refractory Acute Myeloid Leukemia